27/10/2025
🎉 Excited to Announce Our New Publication!
We're thrilled to share our latest research: a Systematic Review and Meta-Analysis on the safety and efficacy of depatuxizumab mafodotin in patients with recurrent glioblastoma.
✨ A Quick Overview:
Our review put depatuxizumab mafodotin under the microscope, looking at its performance alone and when paired with temozolomide. We crunched the numbers on its safety and efficacy for patients battling this tough brain tumor.
🔑 Key Conclusion:
The study suggests that depatuxizumab mafodotin may be a safe and promising treatment option for patients with recurrent glioblastoma, warranting further investigation in clinical trials.
🔍 Read the full publication in the Annals of Medicine & Surgery!